Interestingly, similar observations were made in the context of ARID1A mutations, suggesting that TP53 and ARID1A mutations may contribute to an immunosuppressive microenvironment by suppressing T cell activity, thereby promoting malignant tumor progression. Here, ARID1A is linked to cancer.